Gemopharm is a biopharmaceutical brand that offers innovative products and services in the field of cancer therapy. Their lead candidate, KB-121, is a humanized antibody of the IgG1 isotype. KB-121 specifically binds to the extracellular domain of transferrin receptor type 1 (TfR1), causing its degradation and preventing the entry of iron into cancer cells.

This not only inhibits tumor growth but also activates the antitumor response of cellular immunity. TfR1 is a transmembrane glycoprotein that plays a crucial role in iron transport. Gemopharm's approach disrupts this process, as cancer cells heavily rely on high levels of iron for their rapid growth and survival.

Furthermore, TfR1's interaction with other signaling pathways and its involvement in mitochondrial respiration makes it an appealing target for cancer therapy. Gemopharm's dedication to cutting-edge technology and their team's expertise positions them as a promising brand in the fight against various cancers